This is one more step towards a vaccine to fight against the coronavirus, and it is in Belgium that it is happening. In Wavre more precisely, in the “vaccines” production unit of the pharmaceutical giant GSK. The laboratory is now launching the manufacture of an adjuvant, an important component of a vaccine candidate he is developing against covid-19.
Increase vaccine effectiveness
This adjuvant had been tested, filtered and formulated for months in the Rixensart research and development center. The first batch is now ready. It will therefore be added to the future vaccine to stimulate an immune response in the patient which will lead to protection against the virus. The addition of this adjuvant should also make it possible to reduce the quantity of antigens per dose and therefore reduce the number of injections.
“This could therefore allow more doses of vaccine to be produced to protect more people more quickly.“GSK announces in a press release.
A billion doses within a year
The pharmaceutical company plans to produce a billion of adjuvant doses by the end of 2021, in particular in Wavre. These doses will be used for the GSK vaccine as such but also by other laboratories which are developing theirs in parallel.
The head of GSK Vaccines in Belgium, Patrick Florent is delighted with this new step taken, “it is a moment of great pride for everyone at GSK and a recognition of the decisive work carried out by all our employees over the past few months. With this pandemic adjuvant, we are doing everything we can to make a vaccine against COVID-19 available as quickly as possible “.
Vaccine for Belgium in early 2021
GSK and its partner in the development of this vaccine, Sanofi, have already concluded sales agreements for a total of more than 732 million doses, including 300 million for the European Union.
With regard to Belgium, the Minister of Health, Frank Vandenbroucke, announced at the beginning of the week in Parliament that our country The first vaccines should be received in the first quarter of next year, thanks to orders for millions of doses, notably through the European Commission.
Receive the main news every morning.
OK Do not show again ×
These were the details of the news GSK begins production of adjuvant in Belgium for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at en24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
